An observational study in Melanoma, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-31.
Sponsored by Institut Claudius Regaud · Observational
In research on melanoma, translational research is the essential link between basic research and clinical research by facilitating the passage between discovery and improvement in the quality of patients care.That is the reason why it is very important to collect, and centralize clinical and biological data of patients with melanoma.
The aim of the project is to provide to scientific community a structured, mixed clinical and biological database, unique in France, in order to insure accessibility to clinical data.
collection of clinical and biological data from patients with melanomas of any stage in a structured and centralized database
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 182 across 438 observational studies indexed under Melanoma.
Browse Melanoma studies →Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with any histological type of melanoma and of any stage
Exclusion Criteria:
collection and centralization of clinical and biological data of patients with melanoma
Database of patients with melanoma
Time frame: 10 years
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Claudius Regaud